{
  "2019_Pipeline_Status":[
    {
      "Phase": "Phase 1",
      "NCT #": "NCT01677572",
      "Drug Name": "Aducanumab (BIIB037)",
      "Status": "Terminated (based on futility analysis conducted on Phase 3 trials, not based on safety concerns",
      "Biomarkers": "PET",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "",
      "Geography": "",
      "Start Date": "2012-10-05",
      "Primary Completion Date": "2019-03-21"
    },
    {
      "Phase": "Phase 1|Phase 2",
      "NCT #": "NCT03493282",
      "Drug Name": "CT1812",
      "Status": "Recruiting",
      "Biomarkers": "CSF or PET",
      "MOA Class": 3,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": 1,
      "Start Date": "2018-04-20",
      "Primary Completion Date": "2020-01-31"
    },
    {
      "Phase": "Phase 1|Phase 2",
      "NCT #": "NCT03801642",
      "Drug Name": "Dapagliflozin",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": "3?",
      "MOA Category": "d",
      "CADRO MOA Category": "J",
      "Geography": 1,
      "Start Date": "2019-01-29",
      "Primary Completion Date": "2020-10-01"
    },
    {
      "Phase": "Phase 1|Phase 2",
      "NCT #": "NCT02414607",
      "Drug Name": "Elderberry Juice",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 3,
      "MOA Category": "c, f",
      "CADRO MOA Category": "M",
      "Geography": 1,
      "Start Date": "2016-09-01",
      "Primary Completion Date": "2019-12-01"
    },
    {
      "Phase": "Phase 1|Phase 2",
      "NCT #": "NCT02054208",
      "Drug Name": "hUCB-MSCs (human umbilical cord blood derived mesenchymal stem cells) NEUROSTEM",
      "Status": "Recruiting",
      "Biomarkers": "PET",
      "MOA Class": "stem cell",
      "MOA Category": "g",
      "CADRO MOA Category": "NGB",
      "Geography": 5,
      "Start Date": "2014-02-01",
      "Primary Completion Date": "2019-07-01"
    },
    {
      "Phase": "Phase 1|Phase 2",
      "NCT #": "NCT03172117",
      "Drug Name": "hUCB-MSCs (human umbilical cord blood derived mesenchymal stem cells) NEUROSTEM",
      "Status": "Recruiting, extension",
      "Biomarkers": "no",
      "MOA Class": "stem cell",
      "MOA Category": "g",
      "CADRO MOA Category": "NGB",
      "Geography": 5,
      "Start Date": "2017-05-19",
      "Primary Completion Date": "2021-12-31"
    },
    {
      "Phase": "Phase 1|Phase 2",
      "NCT #": "NCT02925650",
      "Drug Name": "Posiphen",
      "Status": "Recruiting",
      "Biomarkers": "CSF",
      "MOA Class": 3,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": 1,
      "Start Date": "2017-03-02",
      "Primary Completion Date": "2019-12-31"
    },
    {
      "Phase": "Phase 1|Phase 2",
      "NCT #": "NCT03101085",
      "Drug Name": "S-equol (AUS-131)",
      "Status": "Recruiting",
      "Biomarkers": "No",
      "MOA Class": 3,
      "MOA Category": "c",
      "CADRO MOA Category": "L or M?",
      "Geography": 1,
      "Start Date": "2017-05-05",
      "Primary Completion Date": "2020-03-30"
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03712787",
      "Drug Name": "ABBV-8E12",
      "Status": "Enrolling by invitation - Extension study",
      "Biomarkers": "no",
      "MOA Class": 4,
      "MOA Category": "b",
      "CADRO MOA Category": "B",
      "Geography": "1, 3, 7",
      "Start Date": "2019-03-22",
      "Primary Completion Date": "2026-08-11"
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03461276",
      "Drug Name": "ABvac40",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": 3,
      "Start Date": "2018-02-08",
      "Primary Completion Date": "2022-02-01"
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03790982",
      "Drug Name": "AD-35",
      "Status": "Active, not recruiting",
      "Biomarkers": "no",
      "MOA Class": 1,
      "MOA Category": "e",
      "CADRO MOA Category": "D",
      "Geography": 5,
      "Start Date": "2018-12-01",
      "Primary Completion Date": "2020-12-30"
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03625401",
      "Drug Name": "AD-35",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 1,
      "MOA Category": "e",
      "CADRO MOA Category": "D",
      "Geography": 1,
      "Start Date": "2018-10-04",
      "Primary Completion Date": "2019-07-31"
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03639987",
      "Drug Name": "Aducanumab (EVOLVE)",
      "Status": "Terminated (based on futility analysis conducted on Phase 3 trials and not based on safety concerns)",
      "Biomarkers": "PET",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "",
      "Geography": "",
      "Start Date": "2018-12-20",
      "Primary Completion Date": "2019-07-30"
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT02359552",
      "Drug Name": "Rasagiline",
      "Status": "Completed",
      "Biomarkers": "FDG-PET",
      "MOA Class": 3,
      "MOA Category": "a, c, d",
      "CADRO MOA Category": "J",
      "Geography": "",
      "Start Date": "2015-05-01",
      "Primary Completion Date": "2018-08-29"
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT01703117",
      "Drug Name": "Riluzole",
      "Status": "Recruiting",
      "Biomarkers": "No",
      "MOA Class": 3,
      "MOA Category": "c",
      "CADRO MOA Category": "D",
      "Geography": 1,
      "Start Date": "2013-11-01",
      "Primary Completion Date": "2020-11-01"
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT03462121",
      "Drug Name": "RPh201",
      "Status": "Recruiting",
      "Biomarkers": "MRI or CT",
      "MOA Class": 3,
      "MOA Category": "c",
      "CADRO MOA Category": "E?",
      "Geography": 1,
      "Start Date": "2018-03-01",
      "Primary Completion Date": "2019-12-28"
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT01409915",
      "Drug Name": "Sagramostim (GM-CSF) - Leukine",
      "Status": "Ongoing (trial cacncelled?)",
      "Biomarkers": "PET",
      "MOA Class": 4,
      "MOA Category": "a, c",
      "CADRO MOA Category": "F, A",
      "Geography": 1,
      "Start Date": "2011-03-01",
      "Primary Completion Date": "2020-05-01"
    },
    {
      "Phase": "Phase 3",
      "NCT #": "NCT02477800",
      "Drug Name": "Aducanumab (BIIB037)",
      "Status": "Terminated (based on futility analysis not based on safety concerns; follow up visits and closing out study activities are completed)",
      "Biomarkers": "PET",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": "",
      "Start Date": "2015-08-31",
      "Primary Completion Date": "2019-08-08"
    },
    {
      "Phase": "Phase 3",
      "NCT #": "NCT02484547",
      "Drug Name": "Aducanumab (BIIB037)",
      "Status": "Terminated (based on futility analysis not based on safety concerns; follow up visits and closing out study activities are completed)",
      "Biomarkers": "PET",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": "",
      "Start Date": "2015-09-30",
      "Primary Completion Date": "2019-08-05"
    },
    {
      "Phase": "Phase 3",
      "NCT #": "NCT02346201",
      "Drug Name": "Methylphenidate",
      "Status": "Recruiting",
      "Biomarkers": "No",
      "MOA Class": 2,
      "MOA Category": "e",
      "CADRO MOA Category": "D",
      "Geography": 1,
      "Start Date": "2016-01-01",
      "Primary Completion Date": "2019-12-01"
    },
    {
      "Phase": "Phase 3",
      "NCT #": "NCT03031184",
      "Drug Name": "Mirtazapine",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 2,
      "MOA Category": "e",
      "CADRO MOA Category": "D",
      "Geography": 3,
      "Start Date": "2017-01-01",
      "Primary Completion Date": "2020-01-01"
    },
    {
      "Phase": "Phase 3",
      "NCT #": "NCT03283059",
      "Drug Name": "Octohydroaminoacridine Succinate",
      "Status": "Recruiting",
      "Biomarkers": "MRI",
      "MOA Class": 1,
      "MOA Category": "e",
      "CADRO MOA Category": "D",
      "Geography": 5,
      "Start Date": "2017-08-16",
      "Primary Completion Date": "2020-09-16"
    },
    {
      "Phase": "Phase 3",
      "NCT #": "NCT02008357",
      "Drug Name": "Solanezumab",
      "Status": "Ongoing",
      "Biomarkers": "PET",
      "MOA Class": "c",
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": "1, 6, 7",
      "Start Date": "2014-02-28",
      "Primary Completion Date": "2022-07-22"
    },
    {
      "Phase": "Phase 3",
      "NCT #": "NCT03075241",
      "Drug Name": "Zolpidem & Zoplicone (studied separately)",
      "Status": "Recruiting",
      "Biomarkers": "no",
      "MOA Class": 2,
      "MOA Category": "e",
      "CADRO MOA Category": "D",
      "Geography": 2,
      "Start Date": "2016-10-01",
      "Primary Completion Date": "2020-01-01"
    },
    {
      "Phase": "Phase 2",
      "NCT #": "NCT01767311",
      "Drug Name": "BAN2401",
      "Status": "Ongoing (status changed from Completed status in 2019)",
      "Biomarkers": "PET or CSF",
      "MOA Class": 4,
      "MOA Category": "a",
      "CADRO MOA Category": "A",
      "Geography": "1, 3, 5, 6",
      "Start Date": "2012-12-20",
      "Primary Completion Date": "2022-01-27"
    }
  ]
}